Certara Products - Certara IQ Archives | Page 2 of 4

Publication

Anti-PD-(L)1 Antibodies: Insights From QSP-Based Meta-Analysis

Anti-PD-1 and anti-PD-L1 antibodies have transformed cancer immunotherapy, yet clinical meta-analyses suggest differences in efficacy…

CertaraFebruary 11, 2026

Blog

How Quantitative Systems Pharmacology Addresses Key Challenges in Alzheimer’s Drug Development

Quantitative Systems Pharmacology (QSP) helps address key challenges in Alzheimer’s disease drug development, including tau…

CertaraFebruary 2, 2026

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

CertaraJanuary 14, 2026

Poster

First-in-human dosing model for MDX2004, a novel trispecific CD3xCD28/4-1BB antibody-fusion protein for advanced malignancies

Learn how QSP modeling enabled safe, data-driven FIH dose prediction for the trispecific T-cell activator…

CertaraDecember 16, 2025

Live Events

QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™

Japan: February 26, 2026 - 1:00 - 5:00 pm | Korea: Wednesday, March 4, 2026…

CertaraDecember 9, 2025

Blog

Quantitative Systems Pharmacology Modeling to Support the Preclinical Development of Radiopharmaceuticals

Quantitative Systems Pharmacology (QSP) modeling tackles preclinical radiopharmaceuticals development challenges, from design to dose optimization.

CertaraNovember 14, 2025

Blog

ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™

At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…

CertaraNovember 13, 2025

Guide

De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development

Learn how Early Feasibility Assessment and QSP modeling improve drug design, de-risk feasibility studies, &…

CertaraNovember 7, 2025

Publication

Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk

Immunogenicity poses a significant challenge in biotherapeutics development due to the formation of anti-drug antibodies…

Danielle PillsburyNovember 7, 2025

Press Release

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Discover how Certara IQ accelerates drug development through scalable, QSP Modeling with AI-Powered Biosimulation.

CertaraOctober 30, 2025

Certara Products – Certara IQ

Anti-PD-(L)1 Antibodies: Insights From QSP-Based Meta-Analysis

How Quantitative Systems Pharmacology Addresses Key Challenges in Alzheimer’s Drug Development

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

First-in-human dosing model for MDX2004, a novel trispecific CD3xCD28/4-1BB antibody-fusion protein for advanced malignancies

QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™

Quantitative Systems Pharmacology Modeling to Support the Preclinical Development of Radiopharmaceuticals

ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™

De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development

Towards new approach methodologies for biological therapeutics: a novel model-informed metric to assess immunogenicity risk

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Newsletter sign up

Quick links

Solutions

Contact